{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:42:49Z","timestamp":1787002969188,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01466-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:15:23Z","timestamp":1774458923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-2574","authenticated-orcid":false,"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-0768","authenticated-orcid":false,"given":"Jorge","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-4007","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-3656","authenticated-orcid":false,"given":"Pedro","family":"Asensi Cant\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-6891","authenticated-orcid":false,"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-3405","authenticated-orcid":false,"given":"Joan","family":"Blade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-0752","authenticated-orcid":false,"given":"Shuji","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Nagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafla","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolle","family":"Bonar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Spin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3810-752X","authenticated-orcid":false,"given":"Mostafa","family":"Shokoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhaimen","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8952-3702","authenticated-orcid":false,"given":"Michael E. D.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-6364","authenticated-orcid":false,"given":"Christian","family":"Hampp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Humblet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-2510","authenticated-orcid":false,"given":"Alexander","family":"Breskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-9562","authenticated-orcid":false,"given":"Rachel E.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Jalbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2897-9810","authenticated-orcid":false,"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rodriguez Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1466_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"R Kyle","year":"2009","unstructured":"Kyle R, Rajkumar S. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3\u20139.","journal-title":"Leukemia"},{"key":"1466_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.","journal-title":"Nat Rev Dis Prim"},{"key":"1466_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13:150.","journal-title":"J Hematol Oncol"},{"key":"1466_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1466_CR5","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u201318.","journal-title":"Lancet Oncol"},{"key":"1466_CR6","unstructured":"U.S. Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma 2020. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma."},{"key":"1466_CR7","unstructured":"U.S. Food and Drug Administration. FDA approves first cell-based gene therapy for adult patients with multiple myeloma 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-adult-patients-multiple-myeloma."},{"key":"1466_CR8","unstructured":"U.S. Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma."},{"key":"1466_CR9","unstructured":"U.S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma 2022. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"key":"1466_CR10","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma."},{"key":"1466_CR11","unstructured":"European Medicines Agency. Abecma: European Product Assessment Report - Product Information 2024 Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abecma-epar-product-information_en.pdf."},{"key":"1466_CR12","unstructured":"European Medicines Agency. Carvykti: European Product Assessment Report - Product Information 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf."},{"key":"1466_CR13","unstructured":"European Medicines Agency. Elrexfio: European Product Assessment Report - Product Information 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf."},{"key":"1466_CR14","unstructured":"European Medicines Agency. Tecvayli: European Product Assessment Report - Product Information 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf."},{"key":"1466_CR15","unstructured":"Regeneron. Regeneron\u2019s BCMA\u00d7CD3 bispecific antibody (REGN5458) shows deep and durable responses in patients with heavily-pretreated multiple myeloma in phase 1 2020. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regenerons-bcmaxcd3-bispecific-antibody-regn5458-shows-deep-and."},{"key":"1466_CR16","unstructured":"European Medicines Agency. Lynozyfic: European Product Assessment Report - Product Information 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynozyfic-epar-product-information_en.pdf."},{"key":"1466_CR17","unstructured":"Regeneron. LYNOZYFIC Full Prescribing Information 2025. Available from: https:\/\/www.regeneron.com\/downloads\/lynozyfic_fpi.pdf."},{"key":"1466_CR18","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to linvoseltamab\u2011gcpt for relapsed or refractory multiple myeloma 2025. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma."},{"key":"1466_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2021-144921","volume":"138","author":"JA Zonder","year":"2021","unstructured":"Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138:160.","journal-title":"Blood"},{"key":"1466_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-136307","volume":"136","author":"D Madduri","year":"2020","unstructured":"Madduri D, Berdeja JG, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma. Blood. 2020;136:22\u20135.","journal-title":"Blood"},{"key":"1466_CR21","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312.","journal-title":"J Clin Oncol"},{"key":"1466_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-024-00982-3","volume":"14","author":"YY Li","year":"2024","unstructured":"Li YY, Ge SS, Huang YH, Xu MZ, Wan CL, Tan KW. et al. Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed\/refractory acute myeloid leukemia: results of a pilot study. Blood Cancer J. 2024;14:12","journal-title":"Blood Cancer J"},{"key":"1466_CR23","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1182\/blood-2024-210376","volume":"144","author":"S Kumar","year":"2024","unstructured":"Kumar S, Jagannath S, Weisel KC, Rosi\u00f1ol Dachs L, Dimopoulos M-A, Siegel DS, et al. Comparative effectiveness of linvoseltamab versus current real-world (RW) standard-of-care (SOC) therapies in triple-class exposed relapsed\/refractory multiple myeloma (RRMM): key subgroups analysis. Blood. 2024;144:7039.","journal-title":"Blood"},{"key":"1466_CR24","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328:2446\u20137.","journal-title":"JAMA"},{"key":"1466_CR25","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","volume":"26","author":"HC Lee","year":"2026","unstructured":"Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, et al. Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses. Clin Lymphoma Myeloma Leuk. 2026;26:e201\u2013212.e8.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1466_CR26","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1466_CR27","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1016\/S2152-2650(23)01900-6","volume":"23","author":"S Kumar","year":"2023","unstructured":"Kumar S, Leleu X, Weisel K, Popat R, Suero B, Craigie S, et al. P-282 Ranking importance of prognostic factors for relapsed\/refractory multiple myeloma (RRMM): international physician panel consensus following a systematic review of the literature. Clin Lymphoma Myeloma Leuk. 2023;23:S191\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1466_CR28","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379.","journal-title":"Stat Med"},{"key":"1466_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hern\u00e1n MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656\u201364.","journal-title":"Am J Epidemiol"},{"key":"1466_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550\u201360.","journal-title":"Epidemiology"},{"key":"1466_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377\u201399.","journal-title":"Stat Med"},{"key":"1466_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399\u2013424.","journal-title":"Multivariate Behav Res"},{"key":"1466_CR33","doi-asserted-by":"publisher","first-page":"d2304","DOI":"10.1136\/bmj.d2304","volume":"343","author":"DG Altman","year":"2011","unstructured":"Altman DG, Bland JM. How to obtain the P value from a confidence interval. BMJ. 2011;343:d2304.","journal-title":"BMJ"},{"key":"1466_CR34","unstructured":"Breskin A, Spin P, Wang D, Ma Q, Kroog G, Hampp C. Developing a de\u2011novo mortality model for relapsed and refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data. Pharmacoepidemiol Drug Saf. 2024;33:e5891."},{"key":"1466_CR35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"1466_CR36","doi-asserted-by":"crossref","unstructured":"Siebert U, Brookhart M, Leleu X, Popat R, Setoguchi S, Bonar N, et al. Use of an independent data review committee to promote best practices for external control arms: a case study in relapsed\/refractory multiple myeloma. Value Health. 2025;28:SA47.","DOI":"10.1016\/j.jval.2025.04.1802"},{"key":"1466_CR37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","volume":"41","author":"P Moreau","year":"2024","unstructured":"Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, et al. Comparative effectiveness of teclistamab versus real-world physician\u2019s choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41:696\u2013715.","journal-title":"Adv Ther"},{"key":"1466_CR38","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1007\/s12325-024-02797-x","volume":"41","author":"H Einsele","year":"2024","unstructured":"Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, et al. Comparative efficacy of talquetamab vs. current treatments in the LocoMMotion and MoMMent studies in patients with triple-class-exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41:1576\u201393.","journal-title":"Adv Ther"},{"key":"1466_CR39","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2023-0995","volume":"20","author":"LJ Costa","year":"2024","unstructured":"Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle RP, Sinyavskaya L, et al. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncol. 2024;20:1175\u201389.","journal-title":"Future Oncol"},{"key":"1466_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11:116.","journal-title":"Blood Cancer J"},{"key":"1466_CR41","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","volume":"38","author":"M-V Mateos","year":"2024","unstructured":"Mateos M-V, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma \u2013 2-year follow-up (final analysis). Leukemia. 2024;38:2554\u201360.","journal-title":"Leukemia"},{"key":"1466_CR42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-025-01217-9","volume":"15","author":"L Costa","year":"2025","unstructured":"Costa L, LeBlanc T, Tesch H, Sonneveld P, Johnson S, Vekeman F, et al. An updated indirect comparison of elranatamab versus a real-world external control arm in triple-class refractory multiple myeloma. Blood Lymphat Cancer. 2025;15:11\u201320.","journal-title":"Blood Lymphat Cancer"},{"key":"1466_CR43","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0186","volume":"12","author":"A Krishnan","year":"2023","unstructured":"Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, et al. Teclistamab versus real-world physician\u2019s choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma. J Comp Eff Res. 2023;12:e220186.","journal-title":"J Comp Eff Res"},{"key":"1466_CR44","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. NICE process and methods 2023. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation."},{"key":"1466_CR45","unstructured":"Institute for Quality and Efficiency in Health Care. General methods 2022. Available from: https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-1.pdf."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01466-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01466-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01466-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:50:57Z","timestamp":1774619457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01466-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01466-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CH, JG, OH, AB, JH, WG, RES, JJJ, GSK, KRL, and QM are employees and shareholders of Regeneron Pharmaceuticals, Inc. JH and RES hold shares in Pfizer Inc. NB, PS, MSh, MSi, DW, KH, and MEDW are employees of EVERSANA. EVERSANA consults for various pharmaceutical and medical device companies. SK has received consulting\/advisory role fees from Takeda, Janssen Oncology, Genentech\/Roche, AbbVie, Bristol Myers Squibb\/Celgene, Pfizer, Regeneron, Sanofi, and K36, travel\/accommodation\/expenses from AbbVie and Pfizer, and research funding from Takeda, AbbVie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche\/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, and Bristol Myers Squibb. SJ has received consulting fees from Bristol Myers Squibb, Poseida, Caribou, Genmab, Grail, GSK, Janssen, Legend Biotech, Regeneron, Sanofi, and Takeda, and travel\/accommodation\/expenses from Regeneron, IMS, Legend Biotech, and Poseida. KCW has received research grants, honoraria, and\/or consulting fees from AbbVie, Amgen, Adaptive Biotech, AstraZeneca, Beigene, Bristol Myers Squibb, Cellcentric, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline, and Takeda. LR received honoraria for lectures from Johnson & Johnson, Bristol Myers Squibb, Amgen, Takeda, Sanofi, GSK, Menarini, and Pfizer. XL has received consulting fees from Amgen, Bristol Myers Squibb, GSK, Janssen, Pfizer, Regeneron, Roche, Sanofi, and Takeda. MAD has received honoraria from Amgen, Sanofi, Regeneron, Menarini, Takeda, GSK, Bristol Myers Squibb, Janssen, Beigene, Swixx, and AstraZeneca for participation in advisory boards and satellite symposia. EK has received research grants or contracts from Janssen, GSK, and Pfizer, consulting fees from Janssen, GSK, Pfizer, and Sanofi, honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, GSK, Pfizer, AbbVie, and Sanofi, and travel\/accommodation\/expenses from Janssen. DSS has received honoraria from Merck, Sanofi, Pfizer, Bristol Myers Squibb, Envision Pharma, Sebia, Prothena, K36 Therapeutics, and Roche, and is a current holder of stock options from COTA. JM has received consulting fees from Pfizer, Johnson & Johnson, and Janssen. JD has no relationships to disclose. JdlR has received honoraria from Menarini, Janssen, Takeda, and Oncopharm, has received research funding from Takeda and GSK, and has participated in speakers bureaus for Sanofi, Pfizer, Janssen, and GSK. PAC has no relationships to disclose. JHL has no relationships to disclose. MVM has received honoraria from Janssen, Bristol Myers Squibb\/Celgene, Takeda, Amgen, GSK, AbbVie, Oncopeptides, Sanofi, Pfizer, Regeneron, and Stemline, and membership on an entity\u2019s Board of Directors or advisory committees with Janssen, Bristol Myers Squibb\/Celgene, GSK, AbbVie, Oncopeptides, Sanofi, Pfizer, and Stemline. BP has received honoraria from Johnson & Johnson, Amgen, Sanofi, Bristol Myers Squibb, and Aptitude Health. AG has no relationships to disclose. DD has received consulting fees\/honoraria from Janssen, Gilead, and Amgen, and research funding from Janssen and Amgen. EMO has received consulting fees\/honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Janssen, Menarini Stemline, Oncopeptides, Pfizer, Regeneron, Sanofi, and Takeda, research support from GSK and Oncopeptides, and support for formation from Bristol Myers Squibb, GSK, Janssen, Lilly, and Sanofi. JB has received honoraria for lectures from Janssen, Amgen, Bristol Myers Squibb\/Celgene, and Sanofi. SO has no relationships to disclose. MB served on speakers bureaus for Janssen, Bristol Myers Squibb, Sanofi, Takeda, Menarini Stemline, Pfizer, and GSK, and advisory boards for Janssen, Bristol Myers Squibb, Sanofi, Takeda, Menarini Stemline, Pfizer, GSK, and Regeneron. FE has received honoraria from Johnson & Johnson, Amgen, Takeda, Beigene, Sanofi, and Bristol Myers Squibb, and consultancy fees from Johnson & Johnson, Amgen, Sanofi, and Pfizer. MN has no relationships to disclose. RH has no relationships to disclose. BGMD has received consulting fees from, or performed an advisory role for Amgen, Bristol Myers Squibb, Janssen, and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}